TAT-HuScFv(TAT-HuScFv) - 药物靶点：influenza virus M1_在研适应症：H5N1流感_专利_临床

概要

基本信息

药物类型

抗体

别名-

靶点

influenza virus M1

作用机制

influenza virus M1抑制剂(流感病毒M1蛋白抑制剂)

治疗领域

感染呼吸系统疾病

在研适应症

H5N1流感

非在研适应症-

原研机构

中国农业科学院长春兽医研究所

在研机构

Chinese Academy of Agricultural Sciences

Jilin Agricultural UniversityChangchun First Test of Chinese Patent Medicine Co., Ltd.

非在研机构-

最高研发阶段临床前

首次获批日期-

最高研发阶段(中国)临床前

特殊审评-

关联

100 项与 TAT-HuScFv 相关的临床结果

登录后查看更多信息

100 项与 TAT-HuScFv 相关的转化医学

登录后查看更多信息

100 项与 TAT-HuScFv 相关的专利（医药）

登录后查看更多信息

1

项与 TAT-HuScFv 相关的文献（医药）

2024-05-01·Anticancer Research

Design and Evaluation of a Humanized Anti-EGFR huscFv Antibody Fragment in Combination With Metformin in A549 CellsIn Vitro

Article

作者: Zarate, Xristo ; Arredondo-Espinoza, Eder ; PIOQUINTO-ÁVILA, ELIZETH ; ZARATE, XRISTO ; SOLIS-ESTRADA, JORGE ; González-Cruz, Aldo O ; ARREDONDO-ESPINOZA, EDER ; Solis-Estrada, Jorge ; Pioquinto-Ávila, Elizeth ; BALDERAS-RENTERÍA, ISAÍAS ; Balderas-Rentería, Isaías ; GONZÁLEZ-CRUZ, ALDO O.

BACKGROUND/AIMThe epidermal growth factor receptor (EGFR) is over-expressed in several types of cancer, and monoclonal antibody therapy has been the strategy that has shown the best results. This study focused on the construction of a humanized single chain antibody (huscFv) directed against EGFR (HER1).MATERIALS AND METHODSThe CDR grafting method was used to incorporate murine complementarity determining regions (CDRs) of cetuximab into human sequences. A dot blot assay was used to examine the affinity of the huscFv secreted by HEK293T for EGFR. The inhibitory effect on the viability of A549 cells was evaluated using the WST-1 assay.RESULTSThe incorporation of murine CDRs of cetuximab into human sequences increased the degree of humanness by 16.4%. The increase in the humanization of scFv did not affect the affinity for EGFR. Metformin had a dose-dependent effect, with an IC₅₀ of 46 mM, and in combination with huscFv, the cell viability decreased by 45% compared to the 15% demonstrated by huscFv alone.CONCLUSIONThe CDR grafting technique is efficient for the humanization of scFv, maintaining its affinity for EGFR and demonstrating its inhibitory effect when combined with metformin in A549 cells.

100 项与 TAT-HuScFv 相关的药物交易

登录后查看更多信息

研发状态

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
H5N1流感	临床前	-	Changchun First Test of Chinese Patent Medicine Co., Ltd.	2022-03-31
H5N1流感	临床前	中国	Jilin Agricultural University	2022-03-31
H5N1流感	临床前	中国	Chinese Academy of Agricultural Sciences	2022-03-31